Improving cancer survival is a key challenge identified in 'Improving outcomes: a strategy for cancer (Department of Health, 2011)\'. Cancer survival estimates in England currently fall below those in many European countries across most cancer types ([@bib18]; [@bib27]; [@bib3]; [@bib6]). It has been estimated that if cancer survival in England was made comparable with the European average, then 5000 or more deaths within 5 years of diagnosis could be avoided annually ([@bib1]; [@bib19]). However, if analyses are restricted to include only those who survive at least a year from diagnosis, then the difference in conditional 5-year survival between England and European countries is, in general, smaller ([@bib26]; [@bib11]). This would suggest that differences in 1-year survival are an important driver of differences in longer-term survival.

Stage at diagnosis is highly predictive of cancer mortality, and a possible explanation for the difference in cancer survival between England and Europe is that a higher proportion of patients are diagnosed at a later stage in England ([@bib21]; [@bib9]; [@bib28], [@bib29]). The completeness of stage at diagnosis for cancers registered in England by the NCRS has improved greatly in recent years. Staging completeness now exceeds 80% for several major cancers (including breast, colorectal, lung, ovarian and prostate) diagnosed in 2012, allowing more robust analyses than have previously been possible. The remainder of staging data may be missing for various reasons: certain morphological tumour types have no formal agreed staging system; it was clinically inappropriate to stage the patient; diagnosis and/or treatment was outside the National Health Service; the patient died before staging was complete; or staging information was not transferred to the NCRS.

In England, a National Awareness and Early Diagnosis Initiative was established in 2008 ([@bib20]) as a joint initiative between the Government and Cancer Research UK. Much of its work has focussed on ways of promoting awareness of the early symptoms of cancer to patients and primary-care physicians. The ability to measure stage at diagnosis at a population level is vital to study the impact of such initiatives, study the scale and nature of variation in stage at diagnosis within England and to enable international comparisons.

The purpose of this study is to characterise the stage at presentation for major cancers, which have the highest recorded stage completeness, and to examine the relationship between stage at diagnosis, early mortality and major demographic variables.

Materials and methods
=====================

Details of 156 131 malignant breast, colorectal, lung, prostate and ovarian (ICD-10 C50, C18-20, C34, C61 and C56) tumours diagnosed in 2012 in residents of England were extracted from the NCRS registration data set. Of these, 2663 cases were excluded on the basis that they were a death certificate only registration. Other exclusions comprised the following: 281 male breast cancers; 168 aged under 15 years or over 99 years at diagnosis; 187 recorded as stage 0 -- for breast cancer -- this is Paget\'s disease of the nipple, included under ICD-10 C50; 9 had a misordered date of diagnosis and date of death; and 2 had a missing deprivation quintile. Information on deaths was provided by the Office for National Statistics as part of a routine data feed to NCRS, and follow-up is complete to the end of 2013. Cancers were staged according to the TNM version 7 classification, based on clinical, imaging and pathological information ([@bib22]). The income deprivation quintile was derived by linking each tumour to the Index of Multiple Deprivation 2010 ([@bib4]) using postcode at the time of diagnosis to derive the Lower Statistical Output Area of residence at diagnosis. Equal population quintiles (of the general population) were derived from the income domain score. Geographic area of residence at the time of diagnosis was defined by the strategic clinical networks (SCNs) established in England in 2013. These SCNs have populations ranging from 2.1 to 9.0 million.

Relative survival is the ratio of the observed survival in the patient cohort and the expected survival of a cohort from the general population matched by age, sex, socioeconomic deprivation and geographic region (Government Office Region). It was calculated using the *strs* programme ([@bib8]) with break points set at 1, 3, 6 and 12 months and using the Ederer II method. The life tables used ([@bib2]) were available with background mortality up to 2009. Age-standardised relative survival was calculated using a method of [@bib5].

Observed mortality, expected mortality and person-years of exposure time were calculated using the *strs* command in Stata 12.1 ([@bib25]) for the same periods as for survival. These were summed into an overall excess mortality for the year following diagnosis. This outcome measure was chosen both for simplicity of expression and because mortality in the first year of diagnosis is of wide interest; exploration of the variation in excess mortality within the first year of diagnosis is left for future work. Excess mortality rate ratios were modelled using the *glm* command as per the 'grouped\' methodology of [@bib8] with sex, age band, income deprivation quintile, SCN and stage as independent variables. The baseline SCN for the calculation of rate ratios was selected from one of the two median SCNs in the distribution of 1-year relative survival. Stage 4 was used as the baseline for stage at diagnosis. Interactions between variables were explored by considering further models including an interaction between each pair of variables with a likelihood ratio test performed by comparing the model with and without interactions to determine the significance of each interaction term.

Results
=======

Description of cohort
---------------------

A total of 152 821 newly diagnosed malignant cancers of interest, after exclusions, were diagnosed in England in 2012. [Table 1](#tbl1){ref-type="table"} shows the number of tumours included and the proportion broken down by age, sex, income deprivation, SCN and stage at diagnosis for breast, colorectal, lung, ovarian and prostate cancers. The median age varies between 63.0 years (breast and ovarian cancer) and 70.8 (colorectal) and 71.9 (lung) years, whereas the difference in the proportions of cases occurring in the most and least deprived varies between −11% (lung cancer) and +12% (prostate cancer). There is substantial variation in the stage breakdown with cancer type: more than two-thirds of breast cancers present at stage 1 or 2 and more than two-thirds of lung cancers present at stage 3 or 4. The other three cancers are intermediate between these two distributions. Stage completeness varies between 89% (colorectal cancer) and 82% (prostate cancer).

[Table 2](#tbl2){ref-type="table"} shows the variation in stage at diagnosis by sex, age and income deprivation (variation by SCN is included in the [Supplementary Online Material](#sup1){ref-type="supplementary-material"} and [Supplementary Table 5](#sup1){ref-type="supplementary-material"}). More men with colorectal cancer present at stage 1 compared with women (16 *vs* 14%, *P*\<0.001), whereas for lung cancer slightly fewer men present at stage 1 compared with women (12 *vs* 15%, *P*\<0.001). More men present with stage 4 lung cancer compared with women (50 *vs* 48%, *P*\<0.001).

For all cancer types, the proportion of missing data increases with age, particularly in those aged 80+ years. The proportion of ovarian cancers diagnosed at stage 1 drops from 54.6% in those aged 15--49 years to 19.9% in those aged 70--79 years, whereas there is no statistically significant change in lung cancer. Prostate cancer is intermediate with a change from 45.7 to 33.0%. For colorectal and breast cancer a linear change is not observed, and the highest proportion of stage 1 diagnoses occur in 60--69-year-olds.

The effect of income deprivation on stage distribution is generally \<2.0% between most and least deprived for colorectal and lung cancer, and not statistically significant for ovarian cancer. For breast cancer presentation at stage 1, and at unknown stage, is more common for the least deprived (*P*\<0.001), whereas presentation at stages 2, 3 and 4 is more common in the most deprived (*P*\<0.001). For prostate cancer, presentation at stage 2 (*P*\<0.001) and unknown stage (*P*\<0.05) is more common for the least deprived, whereas presentation at stages 3 (*P*\<0.05) and 4 (*P*\<0.001) is more common in the most deprived.

Variation in relative survival
------------------------------

[Table 3](#tbl3){ref-type="table"} shows relative survival and age-standardised relative survival broken down by the same independent variables. Age standardisation changes overall 1-year relative survival by −0.9% (breast), +1.4% (lung), +1.0% (colorectal), −6.4% (ovarian) and +0.1% (prostate).

For the non-sex-specific cancers, survival is 4.0% higher in men (colorectal cancer) and 5.6% higher in women (lung cancer) compared with the opposite sex. Age-standardised figures are 2.2% for colorectal cancer and 6.1% for lung cancer. Relative survival varies strongly with age but, depending on cancer type, either showed only a small decline up to a certain age and then a steeper decline (breast, colorectal and prostate cancers) or declined with every increment in age category (lung and ovarian cancer). Relative survival decreases with increasing income deprivation, between the least and most deprived by 1.7% (breast), 6.5% (colorectal), 2.6% (lung), 3.0% (ovarian) and 0.8% (prostate). The age-standardised figures are 2.1%, 6.7%, 4.5%, 8.6% and 0.6%, respectively.

The variation of the relative survival between SCNs has a standard deviation of 0.5% (breast), 1.3% (colorectal), 1.6% (lung), 2.6% (ovarian) and 0.8% (prostate), assuming a normal distribution across SCNs. Relative survival is reduced with increasing stage; again some cancer types show a small reduction for lower-stage categories (breast, colorectal and prostate) followed by larger reductions in higher-stage categories, whereas other cancer types (lung and ovarian) show substantial reductions for each increase in stage at diagnosis.

Variation in excess mortality rate ratio
----------------------------------------

[Table 4](#tbl4){ref-type="table"} shows the excess mortality rate ratio for each independent variable. For early-stage breast and stage 1--3 prostate cancers, the mortality rate ratio is close to zero (relative to the baseline case of stage 4). Of the independent variables, stage and age have the greatest influence. Women have 14% higher excess mortality for colorectal cancer and 13% lower for lung cancer than men (*P*\<0.001 for both). Rate ratios increase with increasing age and increasing deprivation, and they are statistically significant for each cancer type for older ages compared with the youngest group. Except for prostate cancer, higher income deprivation is associated with higher excess mortality. There is some statistically significant variation in the rate ratios geographically, with 5 out of 50 combinations of cancer types and SCN being statistically significant at a 95% level.

Interactions and robustness
---------------------------

Of the 38 possible pairwise interaction terms across the five cancer types, 19 were significant at a 95% level in a likelihood ratio test comparing the model with and without interaction terms. Of these five were between stage and SCN and due to geographic variation in excess mortality by unknown stage. Four were associated with small subcohorts and showed no clear pattern in the excess mortality. Four were significant overall but had no individual combination of joint variables that was significant. One was owing to high excess lung cancer mortality in the N58 network being concentrated in the most-deprived quintile. One interaction between sex and stage was because of colorectal cancer excess mortality being higher in women specifically for stage 3, and one interaction between sex and age was because of worse colorectal outcomes in older women compared with men. Finally, there were four significant interactions between age and stage (data shown in [Supplementary Table 6](#sup1){ref-type="supplementary-material"}) because of higher colorectal and ovarian cancer mortality in older persons with stage 3 cancer and worse lung cancer outcomes in stage 1 and stage 2 lung cancer in persons aged 80--99 and 90--99 years. The interaction was also significant for prostate cancer, but no interaction terms were individually significant (and thus this interaction is also counted above).

The effect of using life tables from 2009 was estimated to increase the reported survival by approximately 0.2% compared with an estimate of what would have resulted from using 2012 life tables. This estimate was produced by recalculating survival with 2006 life tables and assuming a linear change in background mortality from 2006 to 2012.

Discussion
==========

The results presented here demonstrate the value of the substantial improvement in the completeness of staging data collected by the NCRS in England. Early-stage presentation is more likely in younger persons for ovarian and prostate cancers, and for screening age for colorectal and breast cancers. Early-stage presentation is (marginally) less likely in the more income-deprived. The analysis clarifies the expected patterns of survival, and it shows that age and stage have the greatest association on the absolute value of the 1-year survival and the adjusted excess mortality rate ratio for early mortality, whereas for sex, income deprivation and geographic area of residence the impact is smaller.

For sex, the fact that the rate ratios are close to unity implies that some of the difference in relative survival by sex is driven by age and stage case-mix, concordant with earlier work ([@bib17]). Excess mortality rate ratios between the least and most deprived of up to 1.4 are seen, and in colorectal cancer the associated difference in relative survival is 6.5%. This rate ratio is broadly in agreement with previously calculated mortality rate ratios of ∼1.1 per increment in income deprivation quintile ([@bib15]) but could also be influenced by variables outside the model, including comorbidity, differential uptake of potentially curative treatment ([@bib16]) and the frequency of emergency presentation, all of which are higher in the more income-deprived.

Examination of the interaction between independent variables considered shows worse outcomes in stage 3 colorectal cancers in women. The relationship between age and stage in colorectal and ovarian cancers (with outcomes worse for stage 3 in older persons) and lung cancer (with outcomes worse for early stages in older persons) may indicate opportunities for re-evaluation of clinical pathways. Geographic variation in the mortality rate for unknown stage cancers is also observed, although this is likely owing to varying stage completeness.

Several SCNs show excess mortality rate ratios that are above unity and statistically significant at a 95% level. This may reflect variation not captured by the model, for example, owing to varying comorbidity, route of presentation or treatment, although, owing to the multiple testing performed, some may be simple random variations. There is significant scope for more work to describe this variation down to much smaller geographical and even health-care provider level, which is likely to be more able to help understand the reasons for such variation.

Major strengths of this study are the high stage completeness, between 80 and 90 percent, and that the data cover the whole population of England. There are four principal limitations of the study. First, the unavailability for this study of route to diagnosis, previously shown to affect short-term survival ([@bib15]), means that some of the excess mortality attributed to older age and higher stage might be a result of differences in route of presentation. However, [@bib15] also found age and stage to be the most predictive independent variables. Second, the study is limited to a single year of data, 2012, complicating the interpretation of the data in comparison with earlier studies. Additionally, during the processing of data from 2012 the registration function of the previous eight regional cancer registries merged to form the National Cancer Registration Service. Standardisation of practice can be expected in the future to improve stage completeness to a consistent level nationally, but some bias in completeness with geography still exists. Third, the model does not capture data on comorbidities. However, the influence of comorbidity on short-term mortality is lower than that of age and stage ([@bib15]), and thus this is unlikely to change the main conclusions of the study. Last, the outcome measured is the excess mortality in the year after diagnosis; although this is calculated by summing the excess mortality across four periods in the year, it does not attempt to characterise any non-proportionality of hazards in this period.

The Office for National Statistics publishes yearly overall cancer survival figures for a number of cancers, currently complete to tumours diagnosed up to 2011 ([@bib24]) and predicted for tumours diagnosed up to 2013 ([@bib23]). Direct comparison with these is complicated by differences in methodology, but for colon and breast (and also for oesophagus and stomach cancers -- shown in [Supplementary Online Material](#sup1){ref-type="supplementary-material"}) cancers the agreement is good -- ∼2% or less between years and generally 1% or less for a direct comparison of 2011. There is a notable difference in lung cancer, with overall relative survival reported here being larger (33.4 in men and 39.4 in women, 2012) than those reported by Office for National Statistics (ONS) (31.6 in men and 34.7 in women, 2011). However, ONS predictions for 2013 are larger again than figures reported here (36.1 in men, 42.2 in women, 2013, predicted). It is possible that the difference may be an artefact explicable by a change in practice in the recording of diagnosis date by the NCRS owing to better access to data from radiological systems and from the National Lung Cancer Audit (NLCA). However, there have been major improvements in the treatment rates for lung cancer, particularly in surgical resection rates, between 2005 and 2012, as demonstrated by the NLCA (Health and Social Care Information Centre, 2013). [@bib12], using NLCA data, showed a significant fall in the hazard ratio of death in early-stage lung cancer between 2005 and 2010, and more recent preliminary data from the NLCA also demonstrates an improvement in overall median and one-year survival for lung cancer patients between 2010 and 2013 (MD [@bib16], personal communication), supporting the increase observed here.

Survival by stage has been previously published for the UK for cancers diagnosed in 2004--07 ([@bib13], [@bib14]; [@bib28], [@bib29]). Again, direct comparison is complicated by differences in methodology and the differing definition of the tumour cohorts. However, it appears that breast and colon cancers exhibit the largest improvement in stage-specific survival for later stage cancers, whereas lung cancer has greater improvements for earlier-stage cancers. Ovarian cancer shows little change in stage-specific survival with the exception of unknown stage, which shows an improvement in all cancers compared. This increase in the survival of unknown cases is consistent with a reduction in the proportion of unknown cases that are of advanced stage.

Implications
------------

The results presented here support the work underpinning campaigns promoting early diagnosis, with survival estimates shown to be better for the cancers diagnosed at earlier stage. For all cancer types examined, diagnosis before stage 4 substantially increases the 1-year survival. For lung and ovarian cancer, any shift to all lower stages at diagnosis brings substantial benefit. For these two latter cancer types, there is also scope for increasing the early-stage-specific survival both by the development of more effective treatments and by ensuring the universal application of best current practice to all suitable patients, in other words reducing the large variations in the standards of care that are known to exist (Health and Social Care Information Centre, 2013).

In conclusion, the completeness of stage at diagnosis will allow more accurate comparisons between England and other countries. It will also allow the frequency of early diagnosis to be investigated more comprehensively, to examine regional and local variations and to enable better assessment of the campaigns aimed at promoting the earlier diagnosis of cancer.
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###### Tumour cohort broken down by cancer type, sex, age, income deprivation, strategic clinical network and recorded stage

                                   **Breast**   **Colorectal**   **Lung**   **Ovarian**   **Prostate**                                 
  -------------------------------- ------------ ---------------- ---------- ------------- -------------- ------ ------ ------ -------- ------
  All                              42 071       100              34 011     100           34 997         100    5455   100    36 287   100
  **Sex**                                                                                                                              
  Male                             0            0                19 215     56.5          19 120         54.6   0      0      36 287   100
  Female                           42 071       100              14 796     43.5          15 877         45.4   5455   100    0        0
  **Age (years)**                                                                                                                      
  Median                           63.0         70.8             71.9       63.0          70.8                                         
  15--49                           8504         20.2             2071       6.1           973            2.8    1077   19.7   405      1.1
  50--59                           8881         21.1             3713       10.9          3445           9.8    956    17.5   3727     10.3
  60--69                           11 002       26.2             8501       25.0          9583           27.4   1369   25.1   12 691   35.0
  70--79                           7193         17.1             10 493     30.9          11 937         34.1   1223   22.4   12 887   35.5
  80--89                           5307         12.6             7857       23.1          7867           22.5   720    13.2   5795     16.0
  90--99                           1184         2.8              1376       4.0           1192           3.4    110    2.0    782      2.2
  **Income deprivation**                                                                                                               
  Least deprived                   9474         22.5             7306       21.5          4723           13.5   1089   20.0   8661     23.9
  Quintile 2                       9573         22.8             7488       22.0          6370           18.2   1225   22.5   8904     24.5
  Quintile 3                       8976         21.3             7298       21.5          7115           20.3   1177   21.6   7704     21.2
  Quintile 4                       7788         18.5             6488       19.1          7961           22.7   1060   19.4   6197     17.1
  Most deprived                    6260         14.9             5431       16.0          8828           25.2   904    16.6   4821     13.3
  **Strategic clinical network**                                                                                                       
  N50                              2148         5.1              1804       5.3           2285           6.5    300    5.5    1831     5.0
  N51                              3233         7.7              2820       8.3           3522           10.1   479    8.8    2772     7.6
  N52                              2553         6.1              2233       6.6           2975           8.5    335    6.1    2036     5.6
  N53                              4078         9.7              3362       9.9           4299           12.3   533    9.8    3381     9.3
  N54                              5042         12.0             4039       11.9          3809           10.9   689    12.6   4705     13.0
  N55                              3874         9.2              3088       9.1           2985           8.5    522    9.6    3206     8.8
  N56                              4464         10.6             3726       11.0          3510           10.0   594    10.9   4175     11.5
  N57                              4133         9.8              3431       10.1          2876           8.2    516    9.5    3648     10.1
  N58                              3660         8.7              3002       8.8           2682           7.7    454    8.3    3299     9.1
  N59                              1702         4.0              1202       3.5           936            2.7    188    3.4    1304     3.6
  N60                              2499         5.9              2049       6.0           1628           4.7    294    5.4    2292     6.3
  N61                              4685         11.1             3255       9.6           3490           10.0   551    10.1   3638     10.0
  **Recorded stage**                                                                                                                   
  Stage 1                          15 752       37.4             5255       15.5          4636           13.2   1711   31.4   11 896   32.8
  Stage 2                          14 148       33.6             8402       24.7          2640           7.5    276    5.1    6269     17.3
  Stage 3                          3583         8.5              9258       27.2          7012           20.0   1567   28.7   5625     15.5
  Stage 4                          2366         5.6              7351       21.6          17 151         49.0   929    17.0   5836     16.1
  Stage NK                         6222         14.8             3745       11.0          3558           10.2   972    17.8   6661     18.4

Abbreviation: NK=not known.

###### Variation in stage at diagnosis by sex, age and income deprivation

                                       **Breast**   **Colorectal**  **Lung**   **Ovarian**   **Prostate**                                  
  ------------------------ ---------- ------------ ---------------- ---------- ------------- -------------- ------- ------ ------- ------- -------
  **Sex**                                                                                                                                  
  Female                    Stage 1      15752          37.4%       2111       14.0%         2395           15.0%    1711   31.4%  ---     ---
  Male                                    ---            ---        3144       16.0%         2241           12.0%    ---     ---   11896   32.8%
  Female                    Stage 2      14148          33.6%       3722       25.0%         1128           7.0%     276    5.1%   ---     ---
  Male                                    ---            ---        4680       24.0%         1512           8.0%     ---     ---   6269    17.3%
  Female                    Stage 3       3583           8.5%       3922       27.0%         3097           20.0%    1567   28.7%  ---     ---
  Male                                    ---            ---        5336       28.0%         3915           20.0%    ---     ---   5625    15.5%
  Female                    Stage 4       2366           5.6%       3215       22.0%         7618           48.0%    929    17.0%  ---     ---
  Male                                    ---            ---        4136       22.0%         9533           50.0%    ---     ---   5836    16.1%
  Female                    Stage NK      6222          14.8%       1826       12.0%         1639           10.0%    972    17.8%  ---     ---
  Male                                    ---            ---        1919       10.0%         1919           10.0%    ---     ---   6661    18.4%
  **Age (years)**                                                                                                                          
  15--49                    Stage 1       2545          29.9%       282        13.6%         126            12.9%    588    54.6%  185     45.7%
  50--59                                  3927          44.2%       526        14.2%         368            10.7%    387    40.5%  1438    38.6%
  60--69                                  5462          49.6%       1647       19.4%         1282           13.4%    389    28.4%  4618    36.4%
  70--79                                  2493          34.7%       1777       16.9%         1704           14.3%    243    19.9%  4247    33.0%
  80--89                                  1132          21.3%       933        11.9%         1036           13.2%     97    13.5%  1332    23.0%
  90--99                                  193           16.3%       90         6.5%          120            10.1%     7     6.4%   76      9.7%
  15--49                    Stage 2       3431          40.3%       384        18.5%         68             7.0%      52    4.8%   84      20.7%
  50--59                                  2832          31.9%       788        21.2%         233            6.8%      60    6.3%   738     19.8%
  60--69                                  3215          29.2%       2019       23.8%         716            7.5%      74    5.4%   2497    19.7%
  70--79                                  2478          34.5%       2836       27.0%         962            8.1%      57    4.7%   2286    17.7%
  80--89                                  1850          34.9%       2104       26.8%         602            7.7%      30    4.2%   625     10.8%
  90--99                                  342           28.9%       271        19.7%         59             4.9%      3     2.7%   39      5.0%
  15--49                    Stage 3       997           11.7%       634        30.6%         171            17.6%    199    18.5%  37      9.1%
  50--59                                  747            8.4%       1216       32.7%         716            20.8%    240    25.1%  587     15.7%
  60--69                                  748            6.8%       2510       29.5%         2104           22.0%    441    32.2%  2157    17.0%
  70--79                                  633            8.8%       2856       27.2%         2420           20.3%    440    36.0%  2148    16.7%
  80--89                                  397            7.5%       1835       23.4%         1425           18.1%    230    31.9%  632     10.9%
  90--99                                   61            5.2%       207        15.0%         176            14.8%     17    15.5%  64      8.2%
  15--49                    Stage 4       363            4.3%       478        23.1%         515            52.9%     87    8.1%   36      8.9%
  50--59                                  385            4.3%       916        24.7%         1874           54.4%    141    14.7%  409     11.0%
  60--69                                  488            4.4%       1790       21.1%         4750           49.6%    258    18.8%  1539    12.1%
  70--79                                  543            7.5%       2144       20.4%         5742           48.1%    257    21.0%  2086    16.2%
  80--89                                  499            9.4%       1723       21.9%         3710           47.2%    157    21.8%  1501    25.9%
  90--99                                   88            7.4%       300        21.8%         560            47.0%     29    26.4%  265     33.9%
  15--49                    Stage NK      1168          13.7%       293        14.1%         93             9.6%     151    14.0%  63      15.6%
  50--59                                  990           11.1%       267        7.2%          254            7.4%     128    13.4%  555     14.9%
  60--69                                  1089           9.9%       535        6.3%          731            7.6%     207    15.1%  1880    14.8%
  70--79                                  1046          14.5%       880        8.4%          1109           9.3%     226    18.5%  2120    16.5%
  80--89                                  1429          26.9%       1262       16.1%         1094           13.9%    206    28.6%  1705    29.4%
  90--99                                  500           42.2%       508        36.9%         277            23.2%     54    49.1%  338     43.2%
  **Income deprivation**                                                                                                                   
  Least deprived            Stage 1       3650          38.5%       1184       16.2%         615            13.0%    347    31.9%  2898    33.5%
  2                                       3704          38.7%       1168       15.6%         842            13.2%    345    28.2%  2874    32.3%
  3                                       3505          39.0%       1207       16.5%         924            13.0%    361    30.7%  2571    33.4%
  4                                       2724          35.0%       918        14.1%         1062           13.3%    343    32.4%  1963    31.7%
  Most deprived                           2169          34.6%       778        14.3%         1193           13.5%    315    34.8%  1590    33.0%
  Least deprived            Stage 2       2965          31.3%       1827       25.0%         363            7.7%      56    5.1%   1536    17.7%
  2                                       3223          33.7%       1879       25.1%         481            7.6%      65    5.3%   1610    18.1%
  3                                       3061          34.1%       1783       24.4%         529            7.4%      64    5.4%   1338    17.4%
  4                                       2702          34.7%       1628       25.1%         587            7.4%      52    4.9%   1066    17.2%
  Most deprived                           2197          35.1%       1285       23.7%         680            7.7%      39    4.3%   719     14.9%
  Least deprived            Stage 3       745            7.9%       2053       28.1%         903            19.1%    321    29.5%  1244    14.4%
  2                                       760            7.9%       2048       27.4%         1290           20.3%    365    29.8%  1406    15.8%
  3                                       766            8.5%       1950       26.7%         1415           19.9%    337    28.6%  1212    15.7%
  4                                       690            8.9%       1733       26.7%         1588           19.9%    280    26.4%  1007    16.2%
  Most deprived                           622            9.9%       1474       27.1%         1816           20.6%    264    29.2%  756     15.7%
  Least deprived            Stage 4       465            4.9%       1522       20.8%         2368           50.1%    179    16.4%  1259    14.5%
  2                                       442            4.6%       1564       20.9%         3080           48.4%    207    16.9%  1365    15.3%
  3                                       457            5.1%       1553       21.3%         3523           49.5%    213    18.1%  1284    16.7%
  4                                       529            6.8%       1459       22.5%         3887           48.8%    189    17.8%  1048    16.9%
  Most deprived                           473            7.6%       1253       23.1%         4293           48.6%    141    15.6%  880     18.3%
  Least deprived            Stage NK      1649          17.4%       720        9.9%          474            10.0%    186    17.1%  1724    19.9%
  2                                       1444          15.1%       829        11.1%         677            10.6%    243    19.8%  1649    18.5%
  3                                       1187          13.2%       805        11.0%         724            10.2%    202    17.2%  1299    16.9%
  4                                       1143          14.7%       750        11.6%         837            10.5%    196    18.5%  1113    18.0%
  Most deprived                           799           12.8%       641        11.8%         846            9.6%     145    16.0%  876     18.2%

Abbreviation: NK=not known.

###### Unadjusted and age-standardised relative survival by cancer type, sex, age, income deprivation, strategic clinical network and recorded stage

                                   **Breast**    **Colorectal**  **Lung**    **Ovarian**  **Prostate**                                                                                                                                                                               
  -------------------------------- ------------ ---------------- ---------- ------------- -------------- ------------ ---------- ------------ ---------- ------------ ---------- ------------ ---------- ------------ ---------- ------------ ----------- -------------- ----------- --------------
  All                              **96.4**        96.2--96.6    **95.6**    95.2--95.9   **77.7**        77.2--78.2  **79.1**    78.6--79.5  **36.3**    35.7--36.8  **37.2**    36.7--37.8  **74.7**    73.5--75.8  **68.3**    66.9--69.6  **96.6**      96.3--96.9   **96.6**      96.3--96.8
  **Sex**                                                                                                                                                                                                                                                                            
  Male                             **---**          **---**      **---**       **---**    **79.4**        78.8--80.0  **80.1**    79.4--80.7  **33.7**    33.0--34.4  **34.4**    78.6--79.5  **---**      **---**    **---**     33.7--35.1  **96.6**      96.3--96.9   **96.6**      96.3--96.8
  Female                           **96.4**        96.2--96.6    **95.6**    95.2--95.9   **75.4**        74.7--76.1  **77.9**    77.2--78.6  **39.3**    38.5--40.1  **40.6**    78.6--79.5  **74.7**    73.5--75.8  **68.3**    39.8--41.3  **---**        **---**     **---**        **---**
  **Age (years)**                                                                                                                                                                                                                                                                    
  15--49                           **98.5**        98.2--98.7    **---**       **---**    **88.1**        86.6--89.4  **---**      **---**    **---**     47.2--53.5  **---**      **---**    **---**     91.2--94.3  **---**      **---**    **---**       96.3--99.3   **---**        **---**
  50--59                           **98.3**        98.0--98.6    **---**       **---**    **86.4**        85.3--87.5  **---**      **---**    **---**     41.3--44.7  **---**      **---**    **---**     86.3--90.4  **---**      **---**    **---**       98.7--99.5   **---**        **---**
  60--69                           **98.0**        97.7--98.3    **---**       **---**    **85.2**        84.4--86.0  **---**      **---**    **---**     41.2--43.2  **---**      **---**    **---**     77.4--81.7  **---**      **---**    **---**       98.7--99.2   **---**        **---**
  70--79                           **95.1**        94.5--95.7    **---**       **---**    **79.5**        78.6--80.3  **---**      **---**    **---**     35.8--37.5  **---**      **---**    **---**     63.6--69.1  **---**      **---**    **---**       97.7--98.5   **---**        **---**
  80--89                           **90.6**        89.5--91.7    **---**       **---**    **65.3**        64.1--66.4  **---**      **---**    **---**     25.1--27.2  **---**      **---**    **---**     36.3--43.8  **---**      **---**    **---**       88.6--90.8   **---**        **---**
  90--99                           **84.5**        81.3--87.5    **---**       **---**    **44.8**        41.7--47.9  **---**      **---**    **---**     14.9--19.7  **---**      **---**    **---**     14.9--32.3  **---**      **---**    **---**       63.1--71.8   **---**        **---**
  Income deprivation                                                                                                                                                                                                                                                                 
  Least deprived                   **97.3**        96.9--97.7    **96.4**    95.8--97.0   **80.4**        79.4--81.4  **81.6**    80.7--82.6  **38.0**    36.6--39.4  **40.1**    38.7--41.6  **78.3**    75.7--80.7  **73.5**    70.4--76.3  **96.9**      96.4--97.4   **96.7**      96.1--97.2
  Quintile 2                       **96.8**        96.3--97.2    **96.2**    95.6--96.8   **78.8**        77.8--79.8  **80.6**    79.6--81.5  **37.0**    35.8--38.3  **38.5**    37.3--39.8  **73.5**    70.9--75.9  **68.4**    65.6--71.0  **96.6**      96.1--97.1   **96.5**      95.9--97.0
  Quintile 3                       **96.6**        96.1--97.1    **95.9**    95.2--96.5   **77.7**        76.7--78.8  **79.2**    78.2--80.2  **35.5**    34.4--36.7  **36.8**    35.6--38.0  **73.9**    71.2--76.4  **67.8**    64.8--70.7  **96.9**      96.3--97.4   **96.9**      96.3--97.4
  Quintile 4                       **95.3**        94.7--95.9    **94.3**    93.5--95.0   **76.3**        75.1--77.4  **77.7**    76.6--78.8  **36.2**    35.1--37.3  **36.9**    35.8--37.9  **72.6**    69.8--75.3  **65.3**    61.9--68.5  **96.3**      95.6--97.0   **96.4**      95.6--97.0
  Most deprived                    **95.6**        95.0--96.2    **94.3**    93.4--95.2   **74.0**        72.7--75.2  **74.9**    73.6--76.1  **35.4**    34.4--36.4  **35.6**    34.6--36.7  **75.3**    72.2--78.1  **64.8**    61.0--68.4  **96.1**      95.2--96.9   **96.1**      95.1--96.8
  **Strategic clinical network**                                                                                                                                                                                                                                                     
  N50                              **95.8**        94.6--96.8    **94.8**    93.2--96.0   **77.7**        75.5--79.7  **78.3**    76.2--80.2  **36.7**    34.7--38.8  **37.3**    35.3--39.4  **73.7**    68.1--78.4  **65.9**    60.0--71.2  **95.9**      94.5--97.1   **95.6**      94.1--96.7
  N51                              **96.6**        95.7--97.4    **95.7**    94.4--96.7   **77.8**        76.1--79.5  **78.2**    76.5--79.8  **36.5**    34.8--38.1  **37.0**    35.4--38.7  **74.8**    70.5--78.5  **67.7**    62.8--72.1  **95.9**      94.8--96.9   **95.9**      94.7--96.8
  N52                              **96.0**        95.0--96.9    **95.2**    93.7--96.3   **76.1**        74.1--78.0  **77.6**    75.7--79.4  **34.7**    33.0--36.5  **35.9**    34.1--37.7  **73.1**    67.9--77.7  **66.4**    60.3--71.8  **97.3**      96.1--98.4   **96.6**      95.0--97.7
  N53                              **96.6**        95.8--97.3    **95.5**    94.4--96.4   **76.6**        75.1--78.2  **78.5**    77.0--79.9  **37.9**    36.4--39.4  **38.8**    37.3--40.4  **74.7**    70.7--78.3  **69.3**    64.6--73.5  **95.7**      94.7--96.6   **95.5**      94.5--96.4
  N54                              **95.9**        95.2--96.5    **95.1**    94.1--95.9   **76.0**        74.6--77.4  **77.8**    76.4--79.1  **35.5**    34.0--37.1  **36.7**    35.1--38.3  **74.5**    71.0--77.7  **68.9**    64.9--72.5  **96.4**      95.6--97.1   **96.7**      95.9--97.3
  N55                              **96.7**        95.9--97.3    **95.4**    94.3--96.4   **76.4**        74.8--78.0  **77.7**    76.1--79.2  **35.9**    34.1--37.6  **37.1**    35.3--38.9  **73.8**    69.7--77.5  **66.0**    61.3--70.3  **95.9**      94.9--96.8   **95.9**      94.9--96.7
  N56                              **96.0**        95.3--96.7    **95.2**    94.2--96.1   **78.2**        76.7--79.6  **79.3**    77.9--80.7  **35.8**    34.2--37.4  **37.0**    35.3--38.7  **76.5**    72.8--79.8  **68.6**    64.3--72.5  **97.8**      97.0--98.5   **97.7**      96.8--98.4
  N57                              **97.3**        96.6--97.9    **96.8**    95.8--97.5   **78.8**        77.3--80.2  **80.5**    79.1--81.9  **35.9**    34.1--37.7  **37.0**    35.1--38.8  **73.4**    69.2--77.1  **68.2**    63.6--72.4  **95.8**      94.8--96.6   **96.2**      95.3--97.0
  N58                              **97.0**        96.2--97.6    **96.3**    95.3--97.1   **77.8**        76.2--79.4  **79.7**    78.1--81.2  **33.0**    31.2--34.8  **33.9**    32.1--35.8  **73.2**    68.7--77.1  **69.0**    64.1--73.3  **97.0**      96.1--97.8   **96.9**      95.9--97.6
  N59                              **97.0**        95.9--97.9    **96.3**    94.5--97.5   **80.2**        77.6--82.5  **81.5**    79.1--83.7  **38.8**    35.6--42.0  **39.3**    36.0--42.5  **81.5**    75.0--86.6  **76.2**    68.4--82.3  **98.1**      96.7--99.1   **97.6**      95.8--98.6
  N60                              **95.8**        94.7--96.7    **94.9**    93.5--96.0   **79.0**        77.0--80.9  **81.4**    79.6--83.1  **36.0**    33.6--38.4  **37.4**    35.0--39.8  **70.8**    65.0--75.8  **66.7**    60.5--72.2  **97.0**      95.9--98.0   **97.4**      96.3--98.2
  N61                              **96.4**        95.7--97.0    **95.4**    94.3--96.3   **79.3**        77.8--80.8  **80.1**    78.6--81.5  **38.9**    37.2--40.5  **39.6**    37.9--41.3  **77.4**    73.5--80.7  **68.8**    63.9--73.1  **97.3**      96.5--98.0   **96.4**      95.4--97.2
  **Recorded stage**                                                                                                                                                                                                                                                                 
  Stage 1                          **100.0**      99.8--100.2    **99.9**    97.4--100.0  **98.1**        97.4--98.6  **98.0**    97.3--98.5  **84.0**    82.8--85.2  **85.1**    84.0--86.2  **98.1**    97.1--98.8  **96.9**    94.5--98.3  **101.2**    100.9--101.4  **101.4**    101.0--101.7
  Stage 2                          **99.5**        99.2--99.7    **99.5**    99.0--99.7   **93.9**        93.2--94.5  **94.6**    93.9--95.1  **69.5**    67.6--71.4  **71.0**    69.2--72.8  **88.6**    84.0--92.1  **87.5**    81.4--91.8  **100.8**    100.4--101.2  **100.8**    100.3--101.3
  Stage 3                          **97.3**        96.5--97.9    **96.5**    95.3--97.4   **89.1**        88.3--89.8  **89.1**    88.3--89.8  **44.6**    43.4--45.8  **45.3**    44.1--46.4  **71.3**    68.9--73.5  **66.6**    64.1--68.9  **100.9**    100.4--101.3  **100.8**    100.3--101.3
  Stage 4                          **66.4**        64.4--68.4    **65.3**    63.1--67.4   **42.5**        41.3--43.6  **43.8**    42.6--44.9  **17.1**    16.5--17.7  **17.6**    17.0--18.2  **51.5**    48.1--54.7  **49.5**    46.2--52.6  **82.7**      81.6--83.8   **85.1**      84.1--86.1
  Stage NK                         **91.3**        90.4--92.1    **91.2**    90.2--92.1   **53.5**        51.8--55.2  **60.2**    58.4--62.0  **25.5**    24.0--26.9  **28.8**    27.1--30.5  **57.0**    53.7--60.1  **55.5**    52.1--58.8  **93.0**      92.1--93.7   **94.8**      94.1--95.4

Abbreviations: ASRS=age-standardised relative survival; CI=confidence interval; NK=not known; RS=relative survival.

###### Modelled excess mortality rate ratio within 1 year of diagnosis by cancer type, sex, age, income deprivation, strategic clinical network and recorded stage

                                    **Breast**   **Colorectal**   **Lung**  **Ovarian**    **Prostate**                                                                                                  
  -------------------------------- ------------ ---------------- ---------- ------------- -------------- --------- ---------- ------------ --------- ------- ------------ --------- ------- ------------ ---------
  **Sex**                                                                                                                                                                                                
  Male                                                                      **1.00**          (Ref.)      \<0.001  **1.00**      (Ref.)     \<0.001                                                           
  Female                                                                    **1.14**        1.08--1.19             **0.87**    0.84--0.89                                                                     
  **Age (years)**                                                                                                                                                                                        
  15--49                               1.00          (Ref.)       \<0.001   1.00              (Ref.)      \<0.001  1.00          (Ref.)     \<0.001   1.00      (Ref.)     \<0.001   1.00      (Ref.)     \<0.001
  50--59                               1.25        0.98--1.59               1.30            1.12--1.52             1.27        1.15--1.40             1.29    0.96--1.74             0.67    0.27--1.65       
  60--69                               1.72        1.38--2.15               1.73            1.50--1.98             1.44        1.32--1.59             2.11    1.63--2.73             0.89    0.38--2.09       
  70--79                               2.64        2.14--3.27               2.67            2.33--3.05             1.83        1.67--2.01             3.53    2.75--4.54             1.42    0.61--3.30       
  80--89                               3.82        3.10--4.70               4.78            4.19--5.45             2.61        2.38--2.86             8.98    7.01--11.5             3.59    1.55--8.33       
  90--99                               6.22        4.76--8.11               7.00            6.02--8.13             3.50        3.13--3.91             14.48   10.5--20.0             8.83    3.77--20.7       
  **Income deprivation**                                                                                                                                                                                 
  Least deprived                       1.00          (Ref.)       \<0.001   1.00              (Ref.)      \<0.001  1.00          (Ref.)     \<0.001   1.00      (Ref.)      0.004    1.00      (Ref.)      0.234
  Quintile 2                           1.16        0.96--1.40               1.08            1.00--1.17             1.08        1.03--1.13             1.15    0.96--1.36             1.01    0.85--1.21       
  Quintile 3                           1.30        1.08--1.56               1.12            1.04--1.21             1.12        1.07--1.17             1.16    0.97--1.38             0.98    0.81--1.18       
  Quintile 4                           1.58        1.32--1.88               1.20            1.11--1.29             1.15        1.10--1.20             1.34    1.12--1.60             1.13    0.93--1.36       
  Most deprived                        1.41        1.16--1.71               1.39            1.28--1.50             1.22        1.17--1.28             1.41    1.16--1.71             1.20    0.98--1.47       
  **Strategic clinical network**                                                                                                                                                                         
  N50                                  1.18        0.88--1.58     \<0.001   1.11            0.98--1.27    \<0.001  1.03        0.96--1.10   \<0.001   1.27    0.96--1.70    0.015    1.07    0.80--1.45    0.004
  N51                                  0.91        0.68--1.23               1.00              (Ref.)               1.00          (Ref.)               1.17    0.91--1.50             0.87    0.66--1.14       
  N52                                  1.23        0.92--1.65               1.12            0.99--1.27             1.00        0.94--1.06             1.39    1.06--1.82             0.74    0.55--1.01       
  N53                                  1.00          (Ref.)                 1.07            0.95--1.19             0.93        0.88--0.98             1.00      (Ref.)               0.94    0.74--1.20       
  N54                                  1.59        1.25--2.03               1.13            1.01--1.25             0.96        0.90--1.01             1.13    0.90--1.43             1.00      (Ref.)         
  N55                                  1.02        0.78--1.33               1.06            0.94--1.19             0.93        0.87--0.99             1.19    0.93--1.52             0.88    0.67--1.15       
  N56                                  1.14        0.88--1.47               0.96            0.86--1.07             0.98        0.92--1.04             0.99    0.77--1.27             0.72    0.56--0.94       
  N57                                  0.96        0.73--1.26               1.08            0.96--1.21             0.98        0.92--1.05             0.98    0.76--1.25             1.09    0.86--1.37       
  N58                                  0.84        0.64--1.10               1.01            0.90--1.13             1.11        1.04--1.19             1.14    0.89--1.47             0.91    0.70--1.17       
  N59                                  0.89        0.62--1.27               0.85            0.72--1.00             1.00        0.91--1.10             0.73    0.49--1.07             0.45    0.26--0.78       
  N60                                  1.82        1.38--2.41               1.07            0.94--1.23             0.98        0.91--1.06             0.86    0.65--1.15             0.98    0.73--1.31       
  N61                                  0.82        0.64--1.05               0.86            0.77--0.97             0.85        0.80--0.90             0.96    0.74--1.23             1.03    0.80--1.33       
  **Recorded stage**                                                                                                                                                                                     
  Stage 1                             ∼0.00            \*         \<0.001   0.02            0.01--0.03    \<0.001  0.08        0.07--0.08   \<0.001   0.04    0.02--0.06   \<0.001   ∼0.00       \*       \<0.001
  Stage 2                              0.01        0.01--0.02               0.06            0.05--0.07             0.16        0.15--0.18             0.19    0.13--0.27             ∼0.00       \*           
  Stage 3                              0.07        0.06--0.09               0.12            0.11--0.13             0.39        0.37--0.40             0.49    0.42--0.56             ∼0.00       \*           
  Stage 4                              1.00          (Ref.)                 1.00              (Ref.)               1.00          (Ref.)               1.00      (Ref.)               1.00      (Ref.)         
  Stage NK                             0.20        0.17--0.23               0.61            0.57--0.65             0.83        0.79--0.86             0.81    0.71--0.94             0.40    0.35--0.47       

Abbreviations: CI=confidence interval; EMRR=excess mortality rate ratio; NK=not known.

*P*-values indicate significance of likelihood ratio test on the inclusion of the variable in the model. \*Non-convergence in model.
